Novartis: Colonic Neoplasms trials
The registry lists 10 Colonic Neoplasms studies with Novartis as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 5Phase 2 2Phase 3 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- LDE225 for Patients With PTCH1 or SMO Mutated TumorsTerminatedNCT02002689Phase 2Results posted
- A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedNCT04294160Phase 1
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- Safety of BKM120 Monotherapy in Advanced Solid Tumor PatientsCompletedNCT01068483Phase 1
- Dose-Escalation Study in Advanced Colon Cancer PatientsCompletedNCT00969046Phase 1
- Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.CompletedNCT00056459Phase 3
- Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT00056446Phase 3
- EPO906 Therapy in Patients With Advanced Colorectal CancerCompletedNCT00035087Phase 2
- Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon CancerTerminatedNCT00006269Phase 3